191 related articles for article (PubMed ID: 29318894)
1. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.
Oetting WS; Wu B; Schladt DP; Guan W; Remmel RP; Dorr C; Mannon RB; Matas AJ; Israni AK; Jacobson PA
Pharmacogenomics; 2018 Feb; 19(3):175-184. PubMed ID: 29318894
[TBL] [Abstract][Full Text] [Related]
2. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.
Oetting WS; Wu B; Schladt DP; Guan W; Remmel RP; Mannon RB; Matas AJ; Israni AK; Jacobson PA
Pharmacogenomics J; 2018 May; 18(3):501-505. PubMed ID: 29160300
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.
Maldonado AQ; Asempa T; Hudson S; Rebellato LM
Pharmacotherapy; 2017 Sep; 37(9):1081-1088. PubMed ID: 28605053
[TBL] [Abstract][Full Text] [Related]
6. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
[TBL] [Abstract][Full Text] [Related]
7. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.
Tavira B; Coto E; Diaz-Corte C; Alvarez V; López-Larrea C; Ortega F
Pharmacogenet Genomics; 2013 Aug; 23(8):445-8. PubMed ID: 23778326
[TBL] [Abstract][Full Text] [Related]
8. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.
Jacobson PA; Oetting WS; Brearley AM; Leduc R; Guan W; Schladt D; Matas AJ; Lamba V; Julian BA; Mannon RB; Israni A;
Transplantation; 2011 Feb; 91(3):300-8. PubMed ID: 21206424
[TBL] [Abstract][Full Text] [Related]
9. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
10. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
11. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
12. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
Liu S; Chen RX; Li J; Zhang Y; Wang XD; Fu Q; Chen LY; Liu XM; Huang HB; Huang M; Wang CX; Li JL
Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
[TBL] [Abstract][Full Text] [Related]
13. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
[TBL] [Abstract][Full Text] [Related]
14. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
15. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
17. CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients.
Liu L; Huang X; Zhou Y; Han Y; Zhang J; Zeng F; Huang Y; Zhou H; Zhang Y
Int Immunopharmacol; 2022 Oct; 111():109164. PubMed ID: 35998509
[TBL] [Abstract][Full Text] [Related]
18. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
20. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]